$CPRX,,,Good write up on this company (below),,EOD
Post# of 22756
(Total Views: 204)
Posted On: 05/13/2017 5:40:43 PM
$CPRX,,,Good write up on this company (below),,EOD Friday had large purchase. AH was calm. Should see good positive volume at opening but may want to keep eyes on it. Price is $1.95: Resistance is $1.95 which it broke several times on Friday: support is around $1.92 or $1.93 then strong support @$1.90.
Stocks Favored By Analysts: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)
May 13, 2017 Rives Staff Writer
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 2.00. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $4.25 also implies significant upside from the current price of $1.95.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares typically trade an average volume of 1151.39 and institutions hold 30.20% of the total shares.
MOVING AVERAGES
We see here that the stock is 11.78% away from the 20-Day Simple Moving Average. Their 50-Day Simple Moving Average is a difference of 18.60% from current levels. Further back, their 200-Day Simple Moving Average is 59.40% difference from today’s price. Currently, the stock is -10.14% from its 50-Day High and 77.27% from the 50-day low.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)‘s stock has performed at 85.71%. Breaking that down further, it has performed 15.38% for the week, 12.07% for the month, 72.57% over the last quarter, 89.32% for the past half-year and 233.28% for this last year.
Stock research firms currently have a positive stance on shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK). Analysts are projecting that the stock will reach $9.00 on a short term (1 year) basis.
The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)’s shares may have a significant upside to the consensus target of 9.00, but how has it been performing relative to the market? The stock’s price is 3.77 and their relative strength index (RSI) stands at 76.66. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) shares are moving 5.90% trading at $3.77 today.
Stocks Favored By Analysts: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)
May 13, 2017 Rives Staff Writer
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 2.00. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $4.25 also implies significant upside from the current price of $1.95.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares typically trade an average volume of 1151.39 and institutions hold 30.20% of the total shares.
MOVING AVERAGES
We see here that the stock is 11.78% away from the 20-Day Simple Moving Average. Their 50-Day Simple Moving Average is a difference of 18.60% from current levels. Further back, their 200-Day Simple Moving Average is 59.40% difference from today’s price. Currently, the stock is -10.14% from its 50-Day High and 77.27% from the 50-day low.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)‘s stock has performed at 85.71%. Breaking that down further, it has performed 15.38% for the week, 12.07% for the month, 72.57% over the last quarter, 89.32% for the past half-year and 233.28% for this last year.
Stock research firms currently have a positive stance on shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK). Analysts are projecting that the stock will reach $9.00 on a short term (1 year) basis.
The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)’s shares may have a significant upside to the consensus target of 9.00, but how has it been performing relative to the market? The stock’s price is 3.77 and their relative strength index (RSI) stands at 76.66. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) shares are moving 5.90% trading at $3.77 today.
(1)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼